Evidence map›Paper›PMID 28611043›Full record

ArticleCancer research2017

Arl13b Promotes Gastric Tumorigenesis by Regulating Smo Trafficking and Activation of the Hedgehog Signaling Pathway.

Jia Shao, Linlin Xu, Limin Chen, Quqin Lu, Xinsheng Xie, Wei Shi, Huanting Xiong, Chao Shi, Xuan Huang, Jinhong Mei and 4 more

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Hedgehog pathway in sarcoma: from preclinical mechanism to clinical application.Journal of cancer research and clinical oncology · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Jia ShaoCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Linlin XuCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Limin ChenCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Quqin LuDepartment of Epidemiology & Biostatistics, School of Public Health, Nanchang University, Nanchang, Jiangxi, China.
Xinsheng XieCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Wei ShiCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Huanting XiongCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Chao ShiCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Xuan HuangCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Jinhong MeiDepartment of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Hai RaoDepartment of Molecular Medicine, University of Texas Health, San Antonio, Texas.
Hua LuDepartment of Biochemistry & Molecular Biology and Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana.
Nonghua LuInstitute of Digestive Disease, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Shiwen LuoCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. shiwenluo@ncu.edu.cn.
Nanchang University · CNThe University of Texas Health Science Center at San Antonio · USTulane University · US

Funding

The Role of Ribosomal Proteins in the P53-MDM2 PathwayR01CA095441 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI LU, HUA · 2002 to 2021
$5.1M
Dual Targeting of the p53 pathway for development of anti-cancer therapyR01CA172468 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI LU, HUA · 2012 to 2016
$1.5M
How a sun protection complex moonlights in proteolysisR01GM118350 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI RAO, HAI · 2016 to 2017
$598k
NCI NIH HHS R01 CA095441NCI NIH HHS R01 CA172468NIGMS NIH HHS R01 GM118350
6 · The paper itself

Abstract

Inhibitors of the Hedgehog (Hh) pathway transducer Smoothened (Smo) have been approved for cancer treatment, but Smo mutations often lead to tumor resistance and it remains unclear how Smo is regulated. In this study, we identified the small GTPase Arl13b as a novel partner and regulator of Smo. Arl13b regulated Smo stability, trafficking, and localization, which are each crucial for Hh signaling. In gastric cancer cells, Arl13b stimulated proliferation, migration, and invasion

Indexed as

ADP-Ribosylation FactorsAdultAgedAnimalsBlotting, WesternCarcinogenesisFemaleFlow CytometryFluorescent Antibody TechniqueHedgehog ProteinsHeterograftsHumansImmunohistochemistryMaleMiceMiddle AgedADP-Ribosylation FactorsARL13B protein, humanHedgehog ProteinsSmoothened ReceptorSMO protein, human

Identifiers

PMID28611043
PMCPMC5540784
OpenAlexW2624809039

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.